Sánchez-Moreno C, Pérez-Martínez C, Salas-Foglia A, Rodríguez-Rivera A, Ureta-Sánchez S, Navarro-Peña G, Aragón-Tovar AR, Preciado-Preciado F, Gutiérrez-Godínez F

Language: Spanish
References: 10
Page: 290-295
PDF size: 147.88 Kb.

ABSTRACT

One hundred ninety one Mexican patients suffering from lower urinary tract obstructive symptoms were included in this trial carried out in 9 centers through out the Mexican Republic. Alfuzosin 10 mg once daily (OD) was administered to 169 patients to evaluate its efficacy and 183 to prove its safety. Efficacy was assessed with the International Prostate Symptom Score and DAN-PSS sex questionnaires, as well as with uroflowmetry, postvoid residual (PVR) urine volume measurement, and observing the Benign Prostatic Hyperplasia (BPH) progression due to the presence of Acute Urinary Retention (AUR) or the need of surgery for obstruction (BPH). The results showed statistically significant improvement of the final IPSS against the basal treatment from 8.0±6.1 to 19.2±6.4 (p‹0.001). The final DAN-PPS sex also improved from 2.6±2.5 to 1.8±2.7. Uroflowmetry showed an increase of 3.0±7.5 mL/sec. The residual urine volume decreased mainly in patients with 100 or 150 mL, and only 3 patients (1.6%) showed BPH development.
With respect to safety, 5 patients (2.7%) withdrawal the trial due to adverse events caused by changes in blood pressure, but these were of no clinical significance.
Therefore, it was concluded that alfuzosin 10 mg once daily (OD) is an effective treatment, with a good safety profile for treating BPH in this Mexican population.

REFERENCES

1. Berry SJ, Coffey DS et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132:474-479.

2. Oishi K, Boyle P et al. Epidemiology and natural history of benign prostatic hyperplasia. In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), Paris 2-5 July 1997, Edited by Denis L et al. 1998:25-59.

3. Holtgreweh L et al. Economics of BPH. In: Proceedings of the international Consultation of Benign Prostatic Hyperplasia (BPH), Paris July 2-5, 1997, edited by Denis L et al., SCI: 51-70.

4. Denis L, McConnell J et al. Recommendations of the International Scientific Committee: The evaluation al treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Proceedings of the International Consultation of Benign Prostatic Hyperplasia (BPH), Paris, July 2-5, 1997, edited by Denis L et al., SCI: 669-684.

5. Raz S, Zeigler M, Caine M. Pharmacological receptors in the prostate. Br J Urol. 1973;45:663-7.

6. Vallancien G. Alpha-blockers in benign prostatic hyperplasia. Urology. 1999;54:773-5.

7. Lef’evre-Borg F, O’Connor SE et al. Alfuzosin, a selective 1-adrenoreceptor antagonist in the lower urinary tract. Br J Pharmacol. 1993;109:1282-9.

8. Martin D, Jammes D, Angel I. Effects of alfuzosin on urethral and blood pressures in conscious male rats. Life Sci. 1995;57:387-391.

9. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37(3):306-13.

10. Hansen BJ, Flyger H, Brasso K et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol. 1995;76(4):451-8.